Comparable stake leader
BML Investment Partners, L.P.
SEC ownership of PMV Pharmaceuticals, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001699382.
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
50/50
Latest evidence
31 Mar 2026
- Public ticker
- PMVP on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
BML Investment Partners, L.P.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
BML Investment Partners, L.P.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
31 Mar 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001699382
- Issuer location
- Princeton, NJ
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of PMV Pharmaceuticals, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BML Investment Partners, ...
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
50/50
Latest evidence
31 Mar 2026
13D/G
13F
3/4/5
Lead comparable stake: 9.9%
13D/G row: BML Investment Partners, L.P.
Showing 1-8 of 50 holder rows.
Quick read
BML Investment Partners, L.P. leads the comparable SEC ownership view at 9.9%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BML Investment Partners, L.P.'s linked filing trail.
Comparable ownership
Top 5
BML Investment Partners, L.P.
9.9%
TANG CAPITAL MANAGEMENT LLC
8.9%
Sio Capital Management, LLC
4.9%
Euclidean Capital LLC
4.9%
ArrowMark Colorado Holdings LLC
3.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BML Investment Partners, L.P. |
13D/G
|
9.9%
|
$6,615,000
5,292,000 shares
|
+$2,527,616 | 31 Dec 2025 |
| TANG CAPITAL MANAGEMENT LLC |
13D/G
13F
Company
|
8.9%
|
$6,702,907
4,720,357 shares
|
$0 | 16 Sep 2025 |
| Sio Capital Management, LLC |
13F
13D/G
Company
|
4.9%
from 13D/G
|
$3,814,959
3,076,580 shares
|
— | 31 Mar 2026 |
| Euclidean Capital LLC |
13D/G
3/4/5
13F
10%+ Owner · Company
|
4.9%
|
$3,284,554
2,627,643 shares
|
$0 | 31 Mar 2026 |
| ArrowMark Colorado Holdings LLC |
13F
13D/G
Company
|
3.7%
from 13D/G
|
$3,562,227
2,872,764 shares
|
— | 31 Mar 2026 |
| ORBIMED ADVISORS LLC |
3/4/5
10%+ Owner
|
9.3%
|
$7,562,442
4,975,291 shares
|
-$2,420,000 | 23 Oct 2025 |
| BML Capital Management, LLC |
13F
Company
|
10%
|
$6,596,800
5,320,000 shares
|
— | 31 Mar 2026 |
| Eversept Partners, LP |
13F
Company
|
4.4%
|
$2,911,966
2,348,360 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$2,420,000.
Buys
$0
Insiders: 0
Sells
$2,420,000
Insiders: 1
Net
-$2,420,000
Shares: -1,500,000
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 1,500,000
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 1,500,000 | $0 | $2,420,000 | -$2,420,000 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-17 of 17 reporting-owner rows connected to PMV Pharmaceuticals, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
17
Largest Forms 3/4/5 holder
INTERWEST PARTNERS X LP
Net 12M change
-$2,420,000
Latest report
04 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| INTERWEST PARTNERS X LP | 10%+ Owner | $10,040,531 | Mixed | 13 Jul 2021 | ||
| ORBIMED ADVISORS LLC | 10%+ Owner | $7,562,442 | -$2,420,000 | -24% | Filing P/S | 23 Oct 2025 |
| Thilo Schroeder | Director | $2,455,861 | Mixed | 06 Oct 2021 | ||
| David Henry Mack | President and CEO, Director | $697,788 | Mixed | 05 Mar 2026 | ||
| Euclidean Capital LLC | 10%+ Owner | $283,431 | Mixed | 11 Jun 2021 | ||
| Robert Ticktin | General Counsel & COO | $105,090 | Filing P/S | 05 Mar 2026 | ||
| Leila Alland | Chief Medical Officer | $102,377 | Mixed | 15 Sep 2023 | ||
| Deepika Jalota | Chief Development Officer | $95,761 | Filing P/S | 05 Mar 2026 | ||
| Michael Carulli | Chief Financial Officer | $92,310 | Mixed | 05 Mar 2026 | ||
| Winston Kung | Coo, Cfo | Mixed | 12 May 2023 | |||
| Laurie Stelzer | Director | Mixed | 04 Jun 2026 | |||
| Arnold J. Levine | Director | Mixed | 04 Jun 2026 | |||
| Carol Giltner Gallagher | Director | Mixed | 04 Jun 2026 | |||
| Richard A. Heyman | Director | Mixed | 05 Jun 2025 | |||
| Charles M. Baum | Director | Mixed | 04 Jun 2026 | |||
| Peter A. Thompson | Director, 10%+ Owner | Mixed | 02 Jun 2021 | |||
| Kirsten Flowers | Director | Mixed | 04 Jun 2026 |
Recent insider transactions for PMV Pharmaceuticals, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Laurie Stelzer | PMVP | Stock Option (right to buy) | Award | 42,000 | 42,000 | 04 Jun 2026 | Direct | |||
| Arnold J. Levine | PMVP | Stock Option (right to buy) | Award | 42,000 | 42,000 | 04 Jun 2026 | Direct | |||
| Carol Giltner Gallagher | PMVP | Stock Option (right to buy) | Gift | 42,000 | 42,000 | 04 Jun 2026 | See footnote | |||
| Carol Giltner Gallagher | PMVP | Stock Option (right to buy) | Gift | -100% | -42,000 | 0 | 04 Jun 2026 | Direct | ||
| Carol Giltner Gallagher | PMVP | Stock Option (right to buy) | Award | 42,000 | 42,000 | 04 Jun 2026 | Direct | |||
| Kirsten Flowers | PMVP | Stock Option (right to buy) | Award | 42,000 | 42,000 | 04 Jun 2026 | Direct | |||
| Charles M. Baum | PMVP | Stock Option (right to buy) | Award | 42,000 | 42,000 | 04 Jun 2026 | Direct | |||
| Michael Carulli | PMVP | Employee Stock Option (right to buy) | Award | 240,000 | 240,000 | 05 Mar 2026 | Direct | |||
| Robert Ticktin | PMVP | Employee Stock Option (right to buy) | Award | 319,270 | 319,270 | 05 Mar 2026 | Direct | |||
| Deepika Jalota | PMVP | Employee Stock Option (right to buy) | Award | 303,310 | 303,310 | 05 Mar 2026 | Direct | |||
| David Henry Mack | PMVP | Employee Stock Option (right to buy) | Award | 744,960 | 744,960 | 05 Mar 2026 | Direct | |||
| David Henry Mack | PMVP | Common Stock | Options Exercise | 95.7% | 220,643 | 451,109 | 27 Oct 2025 | Direct | ||
| David Henry Mack | PMVP | Employee Stock Option (right to buy) | Options Exercise | -100% | -220,643 | 0 | 27 Oct 2025 | Direct | ||
| Orbimed Advisors Llc | PMVP | Common Stock | Sale | -16.7% | $1,520,000 | $1.52 | -1,000,000 | 4,975,291 | 23 Oct 2025 | See Footnotes |
| Orbimed Advisors Llc | PMVP | Common Stock | Sale | -7.72% | $900,000 | $1.80 | -500,000 | 5,975,291 | 10 Sep 2025 | See Footnotes |
* marks a reported price that did not pass the local price check.